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Edited by Michael R. BubbAbstract Processing of precursor proteins by the proprotein
convertases is thought to occur mainly in the trans-Golgi net-
work or post-Golgi compartments. Such cleavage is inhibited
by the prosegment of the convertases. During our studies of
the use of the inhibitory prosegment of PC1, we noticed that a
construct containing the prosegment fused to the C-terminal
secretory granule sorting domain was cleaved in the endoplasmic
reticulum (ER) at a pair of basic residues, best recognized by fur-
in and PC7. This was further conﬁrmed when this construct was
fused at the C-terminus with a KDEL ER-retention signal. This
suggests that the convertases could cleave some substrates within
the ER, possibly by displacing the inhibitory prosegment associ-
ated with them.
 2005 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Limited proteolysis of inactive polypeptide precursors often
generates biologically active proteins and peptides. Such cleav-
age is performed within the secretory pathway by the mamma-
lian serine proteinases related to bacterial subtilisin, known as
the proprotein convertases (PCs). The PC family counts seven
basic-amino acid (aa) speciﬁc kexin-like convertases: furin,
PC1/3, PC2, PC4, PACE4, PC5/6 and PC7/LPC [1]. These en-
zymes speciﬁcally recognize single or paired basic residues
within a general motif (K/R)–(X)n–(K/R)ﬂ, where n = 0, 2, 4
or 6 and X is any amino acid. PCs contain an N-terminal sig-
nal sequence, followed by a prosegment, a catalytic domain
and a P-domain, as well as a C-terminal (CT) segment that
varies between the diﬀerent members. PC1 and PC2 are theAbbreviations: aa, Amino acid; PC, proprotein convertase; ER, end
oplasmic reticulum; CHO, Chinese hamster ovary; WT, wild type
EGFP, enhanced green ﬂuorescent protein
*Corresponding author. Fax: +1 514 987 5542.
E-mail address: seidahn@ircm.qc.ca (N.G. Seidah).
0014-5793/$30.00  2005 Published by Elsevier B.V. on behalf of th
doi:10.1016/j.febslet.2005.09.029-
;
e Federmain convertases of the regulated secretory pathway [1]. Ex-
cept for PC2, the ﬁrst zymogen cleavage of the convertases oc-
curs in the endoplasmic reticulum (ER), and the ﬁnal
activation is thought to occur in the trans-Golgi network
(TGN) or in immature secretory granules. Accordingly, be-
cause of this ordered zymogen activation of PCs, the cleavage
of precursor proteins by the basic-aa speciﬁc PCs is thought to
occur mainly in the TGN, cell surface, endosomes (furin, PC7,
PC5 and PACE4) [2] or immature secretory granules (PC1 and
PC2) [3]. Analysis of the biosynthesis of furin, PC1 and PC2,
PACE4, PC5 and PC7 revealed that their N-terminal proseg-
ment acts as an intramolecular chaperone and, except for
PC2, as a nanomolar inhibitor of its cognate enzyme. Indeed,
expression of the prosegments of furin, PC7, PC5 and PC1 as
independent domains conﬁrmed their inhibitory potency and
revealed that the C-terminus of the prosegment contains the
critical inhibitory elements [4].
We previously showed that the CT segment of PC1 contains
an amphiphatic a-helix that seems to be critical for the sorting
of this enzyme to secretory granules [5,6]. Accordingly, in this
work, we thought to direct the prosegment of PC1 to granules
by fusing its inhibitory domain to the CT granule-sorting do-
main of PC1. Unexpectedly, we observed that this chimera
was rapidly processed very early on in the secretory pathway
at the CT dibasic site of the prosegment. This led to the
hypothesis that convertases may be active on some substrates
within the early secretory pathway. This concept supports
and extends the scope of an earlier observation that misfolded
insulin receptor is processed by furin-like convertases in the
ER [7].2. Materials and methods
2.1. Constructs and antibodies
The prosegment (aa 1–110) and the CT tail (aa 619–753) of mouse
PC1 cDNAs [8] were fused by PCR (RSKR110–619GVEK) and the
cDNA coding for the fusion protein ‘‘proCT’’ was inserted into the
pIRES2-EGFP vector (Clontech). The R110A mutant of the primary
processing site used to generate the ‘‘pro\CT’’ mutant was obtained
generated by PCR. Finally, we also generated a proCT-V5-KDEL
construct inserted into the pIRES2-EGFP vector and in which the
ER-retention signal KDEL was at the CT end. The cDNAs of human
furin, human PACE4, mouse PC5-A/B and rat PC7 [9] cloned into the
pIRES2-EGFP vector were as described. The anti-V5 monoclonal
antibody (V5-mAb) was from Invitrogen and anti-CT mPC1 [10] anti-
bodies were previously described.ation of European Biochemical Societies.
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HEK293 and AtT20 cells were grown at 37 C in DMEM + 10%
FBS (heat inactivated for HEK293) + gentamycin 28 lg/ml; while Chi-
nese hamster ovary (CHO)-K1, FD11 cells were grown in DMEM:F12
(1:1) + 5% FBS + gentamycin 28 lg/ml. HEK293 cells were transfected
by Eﬀectene (Qiagen), while other cell lines were transfected by Lipo-
fectamine 2000 (Invitrogen). Transfections were done in a 35 mm
dishes. Twenty-four hours after transfection, FD11, HEK293 and
AtT20 cells were labelled with 0.2 mCi [35S]Met/Cys (Amersham) for
various periods in RPMI 1640 + 0.5% dialysed FBS + GTM 28 lg/
ml. The diﬀerent cell lines were either analysed as such after the pulse
or chased in their respective growth medium, as described [10]. For
experiments using Western blots, 24 h post-transfection of CHO-K1
or FD11 cells, the latter were then washed and further incubated for
6 h at 37 C in DMEM:F12 (1:1) + GTM 28 lg/ml. Brefeldin A (Cal-
biochem) was used at concentrations of 2.5 lg/ml.
2.3. Immunoprecipitation, Western blot and protein sequencing
Cells were lysed in RIPA buﬀer 1X (100 mM Tris–HCl, pH 8,
300 mM NaCl, 0.2% SDS, 2% NP-40 and 1% sodium deoxycholate)
for 30 min. Immunoprecipitations in RIPA buﬀer 0.5· were performed
with a V5-mAb (1/500) antibody to which was added 30 ll of protein
A/G plus agarose (Santa Cruz biotechnology). We used anti-V5 HRP
(Invitrogen) (1/2000) or anti-CT mPC1 (1/2000) antibodies for Western
blotting. The anti-CT mPC1 antibody was detected with anti-rabbit
HRP antibody (Sigma) (1/10000). Proteins were separated by SDS–
PAGE and visualized by autoradiography with X-OMAT or BIO-
MAX ﬁlms (Kodak). For microsequencing of proCT and pro\CT
products, HEK293 cells were labelled with 1.5 mCi [3H]valine for 4 h
and the products immunoprecipitated, separated by SDS–PAGE and
microsequenced [10].3. Results
3.1. Endoplasmic reticulum cleavage by the PCs
The original aim was to engineer a PC1 inhibitor targeted to
secretory granules. Accordingly, we fused the signal peptide
and the N-terminal inhibitory prosegment (pro) of PC1 [11]
to its CT segment reported to contain an amphiphatic a-helix
critical for targeting to secretory granules [5], thereby generat-
ing a proCT construct (Fig. 1). In order to prevent a PC-Fig. 1. Processing of proCT and pro\CT occurs early in the secretory
pathway of AtT20 and HK293 cells. Transiently transfected cells with
either proCT, pro\CT or empty vector were labelled with [35S]Met/Cys
for either 5 or 15 min (P5; P15) and chased for 15 or 45 min (C15;
C45), and cell lysates analyzed on 14% tricine SDS–PAGE. The
[3H]Val sequence of each product is shown at the top left corner. The
V5-tagged products were immunoprecipitated with a V5 antibody.dependent cleavage at the C-terminus of the prosegment and
to drastically reduce the inhibitory protency of the prosegment
[4], we generated an R110A mutant, whereby the P1 Arg110 of
the primary cleavage site KERSKR110 of the prosegment is
mutated to Ala (called pro\CT; Fig. 1). Both constructs were
tagged at the C-terminus with a V5-epitope. We chose the cor-
ticotroph AtT20 cell line to perform our analyses, since it is a
widely used regulated cell line endowed with secretory granules
and endogenously expressing PC1, some PC2 and their sub-
strate proopiomelanocortin [12]. AtT20 cells transiently
expressing either proCT or pro\CT were pulse-labelled with
[35S]Met/Cys for 5 min (P5) followed by a chase in the absence
of label for 15 (P5C15) and 45 (P5C45) min (Fig. 1). To our
surprise, we found that with a pulse as short as 5 min, the
33-kDa proCT (form A; likely representing the full-length
proCT) was processed to a 21 kDa CT V5-immunoreactive
product (form B; likely representing proCT cleaved at the pri-
mary cleavage site KERSKR110, thus releasing the CT). This
cleavage was not observed with pro\CT that bears an R110A
mutation. Only at 45 min chase do we begin to observe an
intermediate 26 kDa product (form C) in both proCT and
pro\CT, likely representing proCT and pro\CT cleaved at
the secondary cleavage site RRSRR81ﬂ of the prosegment
(Fig. 1). These data suggest that proCT is processed very early
on during its synthesis, possibly in the ER to produce the B-
product. In contrast, the C-form, is obtained later in time
along the secretory pathway, likely in the TGN where most
convertases were reported to be active [2].
In order to obtain suﬃcient amounts of A and B products for
microsequencing, we selected HEK293 cells that are much bet-
ter transiently transfected than AtT20 cells. In HEK293 cells,
proCT and pro\CT are qualitatively similarly processed as in
AtT20 cells (Fig. 1, bottom), with the exception that the proCT
processing is much less eﬃcient, both following pulses of 15 min
(Fig. 1) and 5 min (not shown). Following transient transfec-
tion of HEK293 cells with a proCT recombinant, the cells were
pulse labelled for 4 h with [3H]Val, and the A and B products
microsequenced. The data revealed a Val at sequence position
5 for the A-form of either proCT or pro\CT, in agreement with
it representing the complete proCT or pro\CT following signal
peptidase cleavage at . . .KA27ﬂKRQFV [10]. In contrast, the
21-kDa B-product revealed a Val in positions 2, 6, 8 and 9 dem-
onstrating that it begins following the dibasic cleavage site
RSKR110ﬂGVEKMVNVV, and conﬁrms that form B corre-
sponds to the CT alone. Unfortunately, HEK293 cells did not
produce enough material for sequencing of the C form, and
we can only speculate from its apparent molecular mass that
it likely corresponds to proCT and pro\CT cleaved at the sec-
ondary processing site of the PC1-prosegment [13]. Notably,
treatment of HEK293 cells with the fungal metabolite brefeldin
A (BFA) revealed only form B and not C, suggesting that the
ﬁrst cleavage can occur in the ER, but not the second.
Since proCT is cut very early along the secretory pathway, it
was no longer useful to direct the inhibitory prosegment to
secretory granules and we did not expand on this approach.
Rather, we were intrigued by the fact proCT, and not pro\CT,
is cleaved very early on in the secretory pathway at a typical
basic aa-speciﬁc PC-recognition motif RSKR110ﬂ [14]. Since
such cleavage occurs in the presence of BFA, which causes
the fusion of the ER with most of the Golgi saccules, except
the TGN [15], it was plausible that such processing occurs
within the ER itself. However, the accepted model of PCs
Fig. 3. Newly synthesized proCT is processed by furin. (A) FD11 cells
expressing WT proCT ± furin and (B) HEK293 cells expressing either
proCT (WT) or proCT-KDEL were pulse labelled for 4 and 3 h,
respectively, with [35S]Met/Cys in the presence (+) or absence () of
BFA. The V5-tagged products were immunoprecipitated with a V5
antibody.
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TGN and beyond, since until they reach the TGN they are
thought to be inhibited by their complexed prosegment [2].
However, it was reported that a mutated from of the proinsu-
lin receptor could be cleaved by furin in the ER [7]. Accord-
ingly, we coexpressed proCT or pro\CT with several basic
aa-speciﬁc PCs in FD11 cells that lack endogenous furin in
the presence or absence of BFA (Fig. 2). The data revealed
that proCT is only marginally cleaved in FD11 cells. In con-
trast, in the absence of BFA, coexpression of either furin,
PC7, PC5-A, and less so PC5-B and PACE4, generated the se-
creted B-form (Fig. 2). In the presence of BFA, the same en-
zymes are still able to process proCT in the cells, with furin
and PC7 being the best proCT convertases. In contrast, the
form C obtained from either proCT or pro\CT is observed
mainly in the absence of BFA, in accordance with it mostly
occurring later along the secretory pathway. All the PCs are
able to cut at the secondary site or proCT in the absence of
BFA, but PC7 is the worse, as some pro\CT is still secreted
in the presence of this convertase (Fig. 2). These results indi-
cate that of all the tested PCs, furin and PC7 could be active
in the ER.
We next used furin R75A that has a mutation in the second-
ary cleavage site of the prosegment. This mutant is cleaved at
the primary cleavage RTKR107ﬂ site but can no longer be
cleaved at the secondary RGVTKR75 site, and hence the pro-
segment remains non-covalently associated with the enzyme
[16]. Since it is believed that furin is activated only when
cleaved at the secondary site [2], we would expect that in the
ER both furin or furin R75A would not be active, and furin
R75A would remain inactive even in the TGN. The data in
Fig. 2, revealed that wild-type (WT) furin can process proCT
and pro\CT, even in the presence of BFA. We now also show
that the same conclusion can be reached for furin R75A
(Fig. 2). These results argue for the possibility that in the ER
proCT can displace the prosegment of furin and be cleaved
by the liberated enzyme.Fig. 2. Western blot analyses of proCT and pro\CT processing by
each convertase in FD11 cells and media in the presence (+) or absence
() of BFA using a CT-PC1 antibody.However, since we detected proCT by Western blot, we can-
not distinguish between the materials synthesized during the
treatment with BFA from that accumulated in the cell before
treatment. Accordingly, following a 4-h radiolabelling pulse
with [35S]Met/Cys experiments, we analysed the maturation
of neo-synthesized proCT by furin in FD11 cells (Fig. 3A).
Our data show that furin cleaves neo-synthesized proCT at
the primary site (form B) in the presence and absence of
BFA, but the form C is generated by furin only in the absence
of this agent (see media). Note that the B-form is weaker in this
radiolabelling experiment than in the one detected by Western
blot in Fig. 2, likely due to an overnight accumulation of this
product as opposed to that observed in the 4-h pulse. Thus, we
can conclude that PCs (at least furin) can cleave proCT in the
ER.
In order to further demonstrate the validity of this conclu-
sion, we generated a proCT-V5-KDEL construct in which
the ER-retention signal KDEL [17] was fused to the C-termi-
nus of proCT-V5. This CT sequence was reported to bind a
speciﬁc seven transmembrane receptors causing the retrieval
of the cognate protein back to the ER from the cis-Golgi
[18]. Upon expression of this construct in either FD11 cells sta-
bly expressing furin (not shown) or in HEK293 cells, we still
clearly observed the production of signiﬁcant amounts of the
B and C forms (Fig. 3B), whereas the WT protein lacking
the ER-retention signal was mostly secreted as an unprocessed
A-form from this cell line (Fig. 3B).4. Discussion
Cleavage of secretory precursors by the PCs is a major
post-translational modiﬁcation that regulates the biological
activity of these proteins. It is therefore critical that such
processing be very well controlled. It is thought that pH
5624 A. Salvas et al. / FEBS Letters 579 (2005) 5621–5625and calcium are major determinants that deﬁne when and
where these convertases are activated. For example, while
furin, PC7, PACE4 and PC5 are active at neutral pH,
PC1 and PC2 are only active at acidic pHs in accordance
with their roles in dense core secretory granules. A number
of engineered variants of protein-based inhibitors that pos-
sess a furin-like motives [2,9] were proposed as PC-inhibitors
within the constitutive secretory [9]. The only temporary
inhibitors that can enter granules are proSAAS [19] and
7B2 [20], the endogenous binding proteins of PC1 and
PC2, respectively. Attempts to direct the prosegment of
inhibitory CT peptide of 7B2 to granules using enkephalin-
derived chimeras were not successful [21], nor were chimeras
of the prosegment of PC1 with the inhibitory segment of
proSAAS [22].
In this work, we also were not successful in directing a
chimera of the prosegment of PC1 fused to the CT secretory
granule sorting domain of PC1 [5]. The main problem we
encountered was the rapid processing of the prosegment
with the ER at the dibasic primary activation site of proPC1
(Fig. 1). This unexpected result led us to deﬁne that furin
and PC7 were the best enzymes (Fig. 2) responsible for this
early processing (Fig. 3) of proCT. Indeed, processing did
occur even in the presence of a KDEL ER-retention signal
at the C-terminus of proCT (Fig. 3B). It was thought that
the PCs are inactive in the ER, principally because of their
complex formation with their inhibitory prosegment. The
data presented in this work and the complementary ones
with proinsulin [7], clearly showed that some substrates
could be cleaved in the ER. Therefore, it is likely that the
exposure of the processing sites of PC-substrates also plays
a critical role in regulating the cleavage kinetics. In the neu-
tral pH environment of the ER, it is likely that the proseg-
ment has more aﬃnity with the cognate enzyme than the
substrate, thereby keeping the enzyme activity in check.
Only, when a competitive substrate is expressed can this
complex be disturbed and the prosegment displaced to allow
for cleavage of this protein. Three cases are now known
where such ER processing by furin can take place: a natural
mutant proinsulin-receptor (Pro62-IR) [7], mutants of profu-
rin (Y65A and F67A) that are retained in the ER but can
process pro-von Willebrand factor [23], and in this work
the proCT chimera that is also cleaved by PC7 (Fig. 2).
We speculate that proCT can displace the prosegment of
the membrane bound furin and PC7 in the ER allowing
for its cleavage in this early compartment. In fact, it was
shown that swapping the prosegment of PC1 by that of fur-
in resulted in a functional PC1 enzyme [24], suggesting that
these prodomains may share common regulatory features.
Finally, the fact that the furin R75A mutant was also able
to process proCT (Fig. 2), while it is unable to cleave small
ﬂuorogenic substrates [16], also agrees with our prosegment
displacement hypothesis.
In conclusion, while it is true that most substrates of the PCs
are processed in the TGN or later along the secretory pathway,
in situations where the substrate is favoured over the inhibi-
tory prosegment of the convertase, cleavage can occur in early
secretory compartments. This may add further plasticity to the
system allowing the generation of cleavage products which
would then be directed towards destruction by the proteasome,
as is the case of Pro62-IR [7], or which could have their own
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